We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Regulatory watch: leading hedgehog inhibitor submitted for approval as skin cancer drug.
- Abstract
The article reports that Genentech Inc., presented a new drug application called Hedgehog (HH) pathway inhibitor for vismodegib, to the U.S. Food & Drug Administration for approval. It mentions that HH pathway inhibitor shows a promisinbg result for basal cell carcinoma (BCC). James K, Chen, Department of Chemical and Systems Biology in Stanford University School of Medicine, states that the HH signaling pathway can avoid the side effects of the conventional chemotherapies.
- Subjects
UNITED States; GENENTECH Inc.; UNITED States. Food &; Drug Administration; BASAL cell carcinoma treatment; CHEN, James K.; STANFORD University. School of Medicine; DRUG side effects; INDUSTRIAL laws &; legislation; DRUG approval laws; CLINICAL trial laws; THERAPEUTIC use of antineoplastic agents; PROTEINS; PYRIDINE; DRUG approval; CLINICAL trials; INDUSTRIES; SKIN tumors; AMIDES; ANIMALS; CHEMICAL inhibitors
- Publication
Nature Reviews Drug Discovery, 2011, Vol 10, Issue 11, p802
- ISSN
1474-1776
- Publication type
journal article
- DOI
10.1038/nrd3594